Plasma β-amyloid in Alzheimer's disease and vascular disease
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Implementation of amyloid biomarkers in clinical practice would be accelerated if such biomarkers could be measured in blood. We analyzed plasma levels of Aβ42 and Aβ40 in a cohort of 719 individuals (the Swedish BioFINDER study), including patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), Alzheimer’s disease (AD) dementia and cognitively healthy elderly, using a ultrasensitive immunoassay (Simoa platform). There were weak positive correlations between plasma and cerebrospinal fluid (CSF) levels for both Aβ42 and Aβ40, and negative correlations between plasma Aβ42 and neocortical amyloid deposition (measured with PET). Plasma levels of Aβ42 and Aβ40 were reduced in AD dementia compared with all other diagnostic groups. However, during the preclinical or prodromal AD stages (i.e. in amyloid positive controls, SCD and MCI) plasma concentration of Aβ42 was just moderately decreased whereas Aβ40 levels were unchanged. Higher plasma (but not CSF) levels of Aβ were associated with white matter lesions, cerebral microbleeds, hypertension, diabetes and ischemic heart disease. In summary, plasma Aβ is overtly decreased during the dementia stage of AD indicating that prominent changes in Aβ metabolism occur later in the periphery compared to the brain. Further, increased levels of Aβ in plasma are associated with vascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Correlations between plasma and CSF Aβ and between plasma Aβ and [18F]flutemetamol SUVR. (A–C) Plasma (Simoa immunoassay) and CSF (Euroimmun immunoassay) Aβ42 and Aβ40 were measured in a cohort of 719 individuals (174 SCI, 214 MCI, 57 AD patients and 274 controls). (D–F) Neuocortical amyloid deposition was measured using [18F]flutemetamol PET in a cohort of 340 individuals (103 SCI, 112 MCI patients and 125 controls). Correlation coefficients (r) and p-values are from Pearson’s correlation analysis. AD, Alzheimer’s disease; CSF, cerebrospinal fluid; SCD, subjective cognitive decline; MCI, mild cognitive impairment; PET, positron emission tomography; SUVR, standardized uptake value ratio.](https://figures.cochat.ai/paper-figures/71bfab0f50314c6182d3ebedc2d5d0c6/plasma-amyloid-in-alzheimer-s-disease-and-vascular-disease-figure-1.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“more recent studies have demonstrated that it correlates with brain Aβ and can differentiate patients with AD from healthy control participants.12,13”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many candidate blood biomarkers have failed in replication studies,7,8 but somewhat promising results have been seen for plasma tau, neurofilament light chain (NFL), and combinations of Aβ42 and Aβ40.9,10,11,12,13,14,15,16,17”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [13]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“a 65-year-old woman with only amyloid biomarkers but who is cognitively normal and has no neurodegeneration has a 10-year Alzheimer's disease risk of 2·5% and a man 2·3%, but the risk is higher with accompanying neurodegeneration (table 2 ).185”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [185]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A model of lifetime risks of people who are amyloid positive without any other biomarkers finds it to be 8·4% for a 90-year-old woman who is cognitively normal at baseline, 23·5% for a 75-year-old woman and 29·3% for a 65-year-old woman.185”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [185]
Experimental — accuracy not yet measuredIn the citing paper
“Although previous studies have found associations between CSF and PET Aβ and plasma Aβ using different immunoassays,7,12,13,14,44,45 the present Elecsys assays produced among the best accuracies and they are the first fully automated assays to have these greater accuracies.”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationRissin, D. M., Kan, C. W., Campbell, T. G., Howes, S. C., Fournier, D. R., Song, L., Piech, T., Patel, P. P., Chang, L., Rivnak, A. J., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1641 · Cited by 2,119
Self-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citationA New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT
Wahlund, L. O., Barkhof, F., Fazekas, F., Bronge, L., Augustin, M., Sjögren, M., Wallin, A., Ader, H., Leys, D., Pantoni, L., et al. (2001) · Stroke · doi:10.1161/01.str.32.6.1318 · Cited by 1,797
Plasma phospholipids identify antecedent memory impairment in older adults
Mapstone, M., Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., MacArthur, L. H., Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., et al. (2014) · Nature Medicine · doi:10.1038/nm.3466 · Cited by 1,043
Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease
Bell, R. D., & Zlokovic, B. V. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0522-3 · Cited by 860
Research works printed but not linked: 1
- Janelidze, S. et al. CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease. Annals of Clinical and Translational Neurology (In press).
Cited by
Items 201–300 of 628
Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers
Thal, D. R., Poesen, K., Vandenberghe, R. R., & Meyer, S. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00819-y · Cited by 57
Biomarkers for Alzheimer's disease
Pauwels, E. K. J., Volterani, D., & Marlani, G. (2009) · Drug News & Perspectives · doi:10.1358/dnp.2009.22.3.1354128 · Cited by 42
Amyloid-β as a Blood Biomarker for Alzheimer’s Disease: A Review of Recent Literature
Wang, X., Sun, Y., Li, T., Cai, Y., & Han, Y. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190714 · Cited by 43
Wilczyńska, K., & Waszkiewicz, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113452 · Cited by 43
The Emerging Role of Circular RNAs in Alzheimer’s Disease and Parkinson’s Disease
Zhang, M., & Bian, Z. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.691512 · Cited by 47
Alzheimer’s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint
Alawode, D. O. T., Fox, N. C., Zetterberg, H., & Heslegrave, A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.837390 · Cited by 45
Self-citationHsu, J., Lee, W., Liao, Y., Wang, S., & Fuh, J. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0319-x · Cited by 50
Bridging the Gap Between Fluid Biomarkers for Alzheimer’s Disease, Model Systems, and Patients
Bjorkli, C., Sandvig, A., & Sandvig, I. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00272 · Cited by 48
Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status
Mofrad, R. B., Scheltens, P., Kim, S., Kang, S., Youn, Y. C., An, S. S. A., Tomassen, J., van Berckel, B. N. M., Visser, P. J., van der Flier, W. M., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00873-w · Cited by 44
Dark, H. E., Duggan, M. R., & Walker, K. A. (2024) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acae019 · Cited by 43
Biofluid biomarkers in Alzheimer’s disease and other neurodegenerative dementias
Zetterberg, H., & Bendlin, B. B. (2026) · Nature · doi:10.1038/s41586-025-10018-w · Cited by 59
Self-citationPlasma Aβ (Amyloid-β) Levels and Severity and Progression of Small Vessel Disease
van Leijsen, E. M. C., Kuiperij, H. B., Kersten, I., Bergkamp, M. I., van Uden, I. W. M., Vanderstichele, H., Stoops, E., Claassen, J. A. H. R., van Dijk, E. J., de Leeuw, F., et al. (2018) · Stroke · doi:10.1161/strokeaha.117.019810 · Cited by 43
Fišar, Z., Jirák, R., Zvěřová, M., Setnička, V., Habartová, L., Hroudová, J., Vaníčková, Z., & Raboch, J. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.04.003 · Cited by 39
Atypical Alzheimer Disease Variants
Polsinelli, A. J., & Apostolova, L. G. (2022) · Continuum · doi:10.1212/con.0000000000001082 · Cited by 39
Pascual‐Lucas, M., Allué, J. A., Sarasa, L., Fandos, N., Castillo, S., Terencio, J. V., Sarasa, M., Tartari, J. P., Sanabria, Á., Tárraga, L., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01143-z · Cited by 44
Choi, W.-Y., Lee, W.-K., Kim, T., Ryu, Y.-K., Park, A., Lee, Y.-J., Heo, S., Oh, C., Chung, Y., & Kang, D.-H. (2022) · Nutrients · doi:10.3390/nu14183714 · Cited by 38
Proteases: Pivot Points in Functional Proteomics
Verhamme, I. M., Leonard, S. E., & Perkins, R. C. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8814-3_20 · Cited by 46
Tuna, G., Yener, G., Oktay, G., İşlekel, H., & Kirkali, F. G. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180752 · Cited by 43
Wongchitrat, P., Pakpian, N., Kitidee, K., Phopin, K., Dharmasaroja, P. A., & Govitrapong, P. (2018) · Current Alzheimer Research · doi:10.2174/1567205015666181109103742 · Cited by 40
Hanon, O., Vidal, J., Lehmann, S., Bombois, S., Allinquant, B., Rose, C., Tréluyer, J., Abdoul, H., Gelé, P., Delmaire, C., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12613 · Cited by 39
Gao, H., Liu, M., Zhao, Z., Yang, C., Zhu, L., Cai, Y., Yang, Y., & Hu, Z. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c00370 · Cited by 40
Yamashita, K., Watanabe, S., Ishiki, K., Miura, M., Irino, Y., Kubo, T., Matsui, J., Hagino, K., Iwanaga, S., & Yoshida, T. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.08.066 · Cited by 39
Blood Derived Amyloid Biomarkers for Alzheimer's Disease Prevention
Udeh‐Momoh, C. T., Zheng, B., Matton, A., Novak, G., Kivipelto, M., Jönsson, L., & Middleton, L. T. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.70 · Cited by 43
Jiang, Y., Uhm, H., Ip, F. C., Ouyang, L., Lo, R. M. N., Cheng, E. Y. L., Cao, X., Tan, C. M. C., Law, B. C. H., Ortiz‐Romero, P., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13676 · Cited by 36
Self-citationTwait, E. L., Wu, J.-H., Kamarioti, M., Basten, M., van der Flier, W. M., Gerritsen, L., & Geerlings, M. I. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02739-9 · Cited by 47
ASC specks as a single-molecule fluid biomarker of inflammation in neurodegenerative diseases
Lobanova, E., Zhang, Y. P., Emin, D., Brelstaff, J., Kahanawita, L., Malpetti, M., Quaegebeur, A., Triantafilou, K., Triantafilou, M., Zetterberg, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53547-0 · Cited by 43
Self-citationChen, T., Lai, Y.-H., Ke, T.-L., Chen, J.-P., Lee, Y.-J., Lin, S.-Y., Lin, P.-C., Wang, P., & Cheng, I. H.-J. (2019) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000505435 · Cited by 40
Jing, X., Wang, L., Song, M. L., Geng, H., Li, W., Huo, Y., Huang, A., Wang, X., & An, C. (2024) · Scientific Reports · doi:10.1038/s41598-024-59530-5 · Cited by 41
Lin, L., Wang, S., Xu, W., Hu, Q., Zhang, P., Ke, Y.-F., Huang, J.-H., Ding, K., Li, X., Hou, C., et al. (2022) · BMC Public Health · doi:10.1186/s12889-022-12522-4 · Cited by 41
Blood Biomarkers for Alzheimer’s Disease: Much Promise, Cautious Progress
Keshavan, A., Heslegrave, A., Zetterberg, H., & Schott, J. M. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-016-0241-0 · Cited by 34
Self-citationKim, J. H., Jung, H., Lee, Y., & Sohn, J. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.658860 · Cited by 36
Pillet, L., Taccola, C., Cotoni, J., Thiriez, H., André, K., & Verpillot, R. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0841-7 · Cited by 41
Kononikhin, A. S., Zakharova, N. V., Semenov, S. D., Bugrova, A. E., Brzhozovskiy, A. G., Indeykina, M. I., Fedorova, Y. B., Колыхалов, И. В., Strelnikova, P. A., Ikonnikova, A. Y., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147907 · Cited by 34
Chatterjee, P., Doré, V., Pedrini, S., Krishnadas, N., Thota, R. N., Bourgeat, P., Ikonomović, M. D., Rainey‐Smith, S. R., Burnham, S. C., Fowler, C. J., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220908 · Cited by 39
Silva‐Spínola, A., Lima, M., Leitão, M. J., Bernardes, C., Durães, J., Duro, D., Tábuas‐Pereira, M., Santana, I. J., & Baldeiras, I. (2023) · European Journal of Neurology · doi:10.1111/ene.15762 · Cited by 36
Alzheimer’s disease: From basic science to precision medicine approach
Forloni, G. (2020) · BMJ Neurology Open · doi:10.1136/bmjno-2020-000079 · Cited by 33
Kulichikhin, K. Y., Fedotov, S. A., Rubel, M. S., Zalutskaya, N. M., Zobnina, A. E., Malikova, O. A., Незнанов, Н. Г., Chernoff, Y. O., & Rubel, A. A. (2021) · Prion · doi:10.1080/19336896.2021.1917289 · Cited by 35
Sharma, H. S., Muresanu, D. F., Nozari, A., Lafuente, J. V., Tian, Z. R., Ozkızılcık, A., Manzhulo, I., Mössler, H., & Sharma, A. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.03.009 · Cited by 34
Min, J., Rouanet, J. P., Martini, A. C., Nashiro, K., Yoo, H. J., Porat, S., Cho, C., Wan, J., Cole, S. W., Head, E., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-30167-0 · Cited by 45
Vogelgsang, J. S., Shahpasand‐Kroner, H., Vogelgsang, R., Streit, F., Vukovich, R., & Wiltfang, J. (2018) · Experimental Brain Research · doi:10.1007/s00221-018-5210-x · Cited by 34
Plasma Amyloid-β dynamics in late-life major depression: a longitudinal study
Pomara, N., Bruno, D., Plaska, C. R., Ramos-Cejudo, J., Osorio, R., Pillai, A., Imbimbo, B., Zetterberg, H., & Blennow, K. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02077-8 · Cited by 35
Self-citationÁlvarez-Sánchez, L., Peña-Bautista, C., Ferré-González, L., Balaguer, A., Baquero, M., Casanova-Estruch, B., & Cháfer-Pericás, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021226 · Cited by 32
A critical appraisal of blood-based biomarkers for Alzheimer’s disease
Lista, S., Mapstone, M. E., Caraci, F., Emanuele, E., López‐Ortiz, S., Martín-Hernández, J., Triaca, V., Imbimbo, C., Gabelle, A., Mielke, M. M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102290 · Cited by 32
Cognitive synaptopathy: synaptic and dendritic spine dysfunction in age-related cognitive disorders
Barrantes, F. J. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1476909 · Cited by 41
Albani, D., Marizzoni, M., Ferrari, C., Fusco, F., Boeri, L., Raimondi, I., Jovicich, J., Babiloni, C., Soricelli, A., Lizio, R., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180321 · Cited by 36
Tzekaki, E. E., Papaspyropoulos, A., Tsolaki, M., Lazarou, E., Kozori, M., & Pantazaki, Α. A. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.111178 · Cited by 36
Schubert, C. R., Paulsen, A. J., Pinto, A. A., Merten, N., & Cruickshanks, K. J. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215096 · Cited by 32
Králová, K., Fousková, M., Habartová, L., Fišar, Z., Jirák, R., Raboch, J., & Setnička, V. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.04.002 · Cited by 33
Wojdała, A. L., Bellomo, G., Toja, A., Gaetani, L., Parnetti, L., & Chiasserini, D. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-0659 · Cited by 35
Dong, Y., Hou, T., Li, Y., Liu, R., Cong, L., Liu, K., Liu, C., Han, X., Ren, Y., Tang, S. H., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230932 · Cited by 29
Self-citationTobeh, N. S., & Bruce, K. D. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1259012 · Cited by 38
AD biomarker discovery in CSF and in alternative matrices
Sancesario, G. M., & Bernardini, S. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.08.008 · Cited by 32
The Interplay between Diabetes and Alzheimer’s Disease—In the Hunt for Biomarkers
Kubis-Kubiak, A., Dyba, A. J., & Piwowar, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082744 · Cited by 37
Hirtz, C., Busto, G. U., Bennys, K., Kindermans, J., Navucet, S., Tiers, L., Lista, S., Vialaret, J., Gutierrez, L., Dauvilliers, Y. A., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01188-8 · Cited by 33
Bandara, E. M. S., Asih, P. R., Pedrini, S., Hone, E., Fernando, W. M. A. D. B., & Martins, R. N. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05219-3 · Cited by 38
In vivo Detection of Alzheimer's Disease.
Leuzy, A., Heurling, K., Ashton, N. J., Schöll, M., & Zimmer, E. R. (2018) · Europe PMC (PubMed Central) · Cited by 42
Chiu, M., Lue, L., Sabbagh, M. N., Chen, T., Chen, H. H., & Yang, S. (2019) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000496099 · Cited by 31
Biomarkers in Alzheimer’s disease
Janeiro, M. H., Ardanaz, C. G., Sola-Sevilla, N., Dong, J., Cortés-Erice, M., Solas, M., Puerta, E., & Ramírez, M. J. (2020) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2020-0090 · Cited by 48
The blood biomarkers puzzle – A review of protein biomarkers in neurodegenerative diseases
Barro, C., & Zetterberg, H. (2021) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2021.109281 · Cited by 32
Self-citationSullivan, K., Blackshear, C. T., Simino, J. M., Tin, A., Walker, K. A., Sharrett, A. R., Younkin, S. G., Gottesman, R. F., Mielke, M. M., Knopman, D. S., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012482 · Cited by 29
Relation of plasma β‐amyloid, clusterin, and tau with cerebral microbleeds: Framingham Heart Study
Romero, J. R., Demissie, S., Beiser, A., Himali, J. J., DeCarli, C. S., Levy, D. A., & Seshadri, S. S. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51066 · Cited by 32
In the blood: biomarkers for amyloid pathology and neurodegeneration in Alzheimer’s disease
Toombs, J., & Zetterberg, H. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa054 · Cited by 33
Self-citationNeuropathology, Neuroimaging, and Fluid Biomarkers in Alzheimer’s Disease
Colvee-Martin, H., Parra, J. R., Gonzalez, G. A., Barker, W., & Duara, R. (2024) · Diagnostics · doi:10.3390/diagnostics14070704 · Cited by 34
Zhang, Y., Bi, K., Zhou, L., Wang, J., Huang, L., Sun, Y., Peng, G., & Wu, W. (2024) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s471174 · Cited by 45
Mikkonen, S., Jacksén, J., Roeraade, J., Thormann, W., & Emmer, Å. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b02324 · Cited by 29
Chiu, M., Chen, T., Hu, C., Yan, S., Sun, Y., Liu, B.-H., Chang, Y.-T., Yang, C., & Yang, S. (2020) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102182 · Cited by 36
Shim, J.-E., Kim, Y. J., Hahm, E., Choe, J., Baek, A., Kim, R. M., & You, E. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.117216 · Cited by 33
Kubota, M., Bun, S., Takahata, K., Kurose, S., Momota, Y., Iwabuchi, Y., Tezuka, T., Tabuchi, H., Seki, M., Yamamoto, Y., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01778-8 · Cited by 41
Dai, Y., Molazemhosseini, A., & Liu, C. C. (2017) · Biosensors · doi:10.3390/bios7030029 · Cited by 35
Cheng, C.-K., Tsao, Y., Su, Y., Sung, F., Tai, H.-C., & Kung, W. (2018) · Behavioural Neurology · doi:10.1155/2018/8312346 · Cited by 30
Jacob, M. E., O’Donnell, A., Samra, J. K., Gonzales, M. M., Satizábal, C. L., Pase, M. P., Murabito, J. M., Beiser, A., & Seshadri, S. S. (2022) · The Journal of Frailty & Aging · doi:10.14283/jfa.2022.17 · Cited by 33
Li, Z., Fan, Z., & Zhang, Q. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230799 · Cited by 30
Zhang, Y., Ferreira, P. C. L., Jacobsen, E. P., Bellaver, B., Pascoal, T. A., Snitz, B. E., Chang, C. H., Villemagne, V. L., Ganguli, M., & Karikari, T. K. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13829 · Cited by 25
Krawczuk, D., Kulczyńska‐Przybik, A., & Mroczko, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158132 · Cited by 30
Fluid Candidate Biomarkers for Alzheimer’s Disease: A Precision Medicine Approach
Prete, E. D., Beatino, M. F., Campese, N., Giampietri, L., Siciliano, G., Ceravolo, R., & Baldacci, F. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040221 · Cited by 31
Tsai, H.-H. C., Tsai, L., Lo, Y.-L., & Lin, C. (2021) · Scientific Reports · doi:10.1038/s41598-021-86617-0 · Cited by 29
Pan, F., Huang, Q., Wang, Y., Wang, Y., Guan, Y., Xie, F., & Guo, Q. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.832700 · Cited by 26
Development of a Clinical Risk Score Prediction Tool for 5-, 9-, and 13-Year Risk of Dementia
Ren, L., Liang, J., Wan, F., Wang, Y., & Dai, X. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.42596 · Cited by 29
Prajjwal, P., Marsool, M. D. M., Inban, P., Sharma, B., Asharaf, S., Aleti, S., Gadam, S., Sakini, A. S. A., & Hadi, D. D. (2023) · Disease-a-Month · doi:10.1016/j.disamonth.2023.101557 · Cited by 32
Alzheimer’s Disease: Models and Molecular Mechanisms Informing Disease and Treatments
Nystuen, K., McNamee, S. M., Akula, M., Holton, K. M., DeAngelis, M. M., & Haider, N. B. (2024) · Bioengineering · doi:10.3390/bioengineering11010045 · Cited by 29
Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer’s disease
Hampel, H. J., Vergallo, A., Afshar, M., Akman-Anderson, L., Arenas, J., Benda, N., Batrla, R., Broich, K., Caraci, F., Cuello, A. C., et al. (2019) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2019.21.2/hhampel · Cited by 28
Solje, E., Benussi, A., Buratti, E., Remes, A. M., Haapasalo, A., & Borroni, B. (2021) · Diagnostics · doi:10.3390/diagnostics11050788 · Cited by 29
Sandberg, A., Berenjeno‐Correa, E., Rodriguez, R. C., Axenhus, M., Weiss, S. S., Batenburg, K. L., Hoozemans, J. J. M., Tjernberg, L. O., & Scheper, W. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01141-1 · Cited by 31
A blood-based signature of cerebrospinal fluid Aβ1–42 status
Goudey, B., Fung, B. J., Schieber, C., Faux, N. G., Weiner, M. W., Aisen, P. S. S., Petersen, R. C., Jack, C. R., Jagust, W. J., Trojanowki, J. Q., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37149-7 · Cited by 25
Role of Body-Fluid Biomarkers in Alzheimer’s Disease Diagnosis
Nguyen, T. T., Ta, Q. T. H., Nguyen, T. K. O., Nguyen, T. T. D., & Giau, V. V. (2020) · Diagnostics · doi:10.3390/diagnostics10050326 · Cited by 27
Differential roles of Alzheimer's disease plasma biomarkers in stepwise biomarker‐guided diagnostics
Jang, H., Shin, D., Yoo, H., Zetterberg, H., Blennow, K., González‐Ortiz, F., Ashton, N. J., Day, T. A., Lee, E. H., Yun, J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14526 · Cited by 29
Self-citationIino, T., Watanabe, S., Yamashita, K., Tamada, E., Hasegawa, T., Irino, Y., Iwanaga, S., Harada, A., Noda, K., Suto, K., et al. (2020) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfaa225 · Cited by 23
Gallo, A., Pillet, L., & Verpillot, R. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2021.111452 · Cited by 28
Novel Trends in Electrochemical Biosensors for Early Diagnosis of Alzheimer’s Disease
Valkova, P., & Pohanka, M. (2021) · International Journal of Analytical Chemistry · doi:10.1155/2021/9984876 · Cited by 28
Jiao, B., Liu, H., Guo, L., Liao, X., Zhou, Y., Weng, L., Xiao, X., Zhou, L., Wang, X., Jiang, Y., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.749649 · Cited by 37
Lee, J.-E., Kwon, S., Jin, C., Cho, S., Park, S.-U., Jung, W., Moon, S., Park, J., Ko, C., & Cho, K. (2022) · Pharmaceuticals · doi:10.3390/ph15020174 · Cited by 31
Schirinzi, T., Zenuni, H., Grillo, P., Bovenzi, R., Guerrera, G., Gargano, F., Pieri, M., Bernardini, S., Mercuri, N. B., Battistini, L., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.748599 · Cited by 26
Andersson, E., Schultz, N., Saito, T., Saido, T. C., Blennow, K., Gouras, G. K., Zetterberg, H., & Hansson, O. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01196-8 · Cited by 29
Self-citationTiiman, A., Jelić, V., Jarvet, J., Järemo, P., Bogdanović, N., Rigler, R. W., Terenius, L. Y., Gräslund, A., & Vukojević, V. B. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181144 · Cited by 25
Kwak, D. E., Ko, T., Koh, H. S., Ji, Y. W., Shin, J., Kim, K., Kim, H. Y., Lee, H. K., & Kim, Y. S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227618 · Cited by 25
Present and Future of Blood-Based Biomarkers of Alzheimer’s Disease: Beyond the Classics
Grigoli, M. M., Pelegrini, L. N. D. C., Whelan, R., & Cominetti, M. R. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148812 · Cited by 22
Taşçı, İ., Safer, U., Naharcı, M. İ., Gezer, M., Demir, O., Bozoğlu, E., & Doruk, H. (2017) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317517724000 · Cited by 23
Qin, T., Prins, S., Groeneveld, G. J., van Westen, G. J. P., de Vries, H. E., Wong, Y. C., Bischoff, L. J. M., & de Lange, E. C. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093158 · Cited by 27
Single-molecule studies of amyloid proteins: from biophysical properties to diagnostic perspectives
Wu, J., Cao, C., Loch, R. A., Tiiman, A., & Luo, J. (2020) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583520000086 · Cited by 24
Álvarez‐Sánchez, L., Peña‐Bautista, C., Baquero, M., & Cháfer‐Pericás, C. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215093 · Cited by 26
Metadata
- Authors
- Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C. A., Baker, D., Blennow, K., & Hansson, O.
- Affiliations
- Lund University (SE)
- National Hospital for Neurology and Neurosurgery (GB)
- Quanterix (United States) (US)
- University of Gothenburg (SE)
- Corresponding author
- Janelidze, Shorena
- Hansson, Oskar
- ORCID
- Venue
- Scientific Reports
- Published
- 2016-05-31
- Volume
- 6
- Issue
- 1
- Pages
- 26801-26801
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC4886210
- OpenAlex
- W2414917913
- Cited by
- 626
- References
- 49
- Citations by year
- 2026: 53 · 2025: 59 · 2024: 75 · 2023: 77 · 2022: 80 · 2021: 75 · 2020: 73 · 2019: 59 · 2018: 45 · 2017: 22 · 2016: 6
- FWCI
- 39.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Australian Government
- Crafoordska Stiftelsen
- Lunds Universitet
- Vetenskapsrådet
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- plasma amyloid-beta, amyloid-beta 42, Aβ40, Alzheimer's disease, vascular disease, amyloid biomarkers, cerebrospinal fluid, white matter lesions, cerebral microbleeds, hypertension, diabetes mellitus, ischemic heart disease, mild cognitive impairment, subjective cognitive decline, amyloid PET, amyloid metabolism
- MeSH terms
- Aged, Alzheimer Disease, Female, Humans, Male, Vascular Diseases, Cohort Studies, Biomarkers, Amyloid beta-Peptides, Neocortex, Positron-Emission Tomography, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.